Syngene International Overview
- Year Founded
-
1993
- Status
-
Public
- Employees
-
7,210
- Stock Symbol
-
539268
- Investments
-
6
- Share Price
-
$4.68
- (As of Thursday Closing)
Syngene International General Information
Description
Syngene International Ltd is a contract research, development and manufacturing organization (CRDMO) providing integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies. Its business divisions include Discovery Services, Translational & Clinical Research, Dedicated Centers, and Contract Development and Manufacturing Services. Its services cover lead generation, medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process R&D, cGMP manufacturing, formulation and analytical development, and clinical development services. The Company operates in a single segment of contract research and manufacturing services, with the majority of its revenue derived from the USA.
Contact Information
Website
www.syngeneintl.comCorporate Office
- Biocon Park, SEZ, Bommasandra Industrial Area Phase IV
- Jigani Link Road
- Bangalore, Karnataka 560099
- India
Corporate Office
- Biocon Park, SEZ, Bommasandra Industrial Area Phase IV
- Jigani Link Road
- Bangalore, Karnataka 560099
- India
Syngene International Timeline
Syngene International Stock Performance
As of 19-Nov-2026, Syngene International’s stock price is $4.68. Its current market cap is $1.88B with 402M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.68 | $4.65 | $3.56 - $7.52 | $1.88B | 402M | 143K | $0.05 |
Syngene International Financials Summary
As of 30-Sep-2026, Syngene International has a trailing 12-month revenue of $380M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 1,439,973 | 1,596,296 | 3,353,495 | 3,292,046 |
| Revenue | 379,890 | 408,618 | 415,435 | 407,014 |
| EBITDA | 80,340 | 95,888 | 128,410 | 122,702 |
| Net Income | 20,071 | 35,840 | 58,682 | 61,605 |
| Total Assets | 693,224 | 747,695 | 794,477 | 737,659 |
| Total Debt | 52,826 | 48,584 | 67,560 | 66,576 |
Syngene International Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Syngene International Comparisons
Industry
Financing
Details
Syngene International Competitors (51)
One of Syngene International’s 51 competitors is Pharmaron, a Formerly VC-backed company based in Beijing, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Pharmaron | Formerly VC-backed | Beijing, China | ||||
| Reliance Life Sciences | Corporation | Navi Mumbai, India | ||||
| Eurofins Scientific | Corporation | Luxembourg, Luxembourg | ||||
| WuXi AppTec | Formerly PE-Backed | Shanghai, China | ||||
| Lupin | Corporation | Mumbai, India |
Syngene International Patents
Syngene International Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240158394-A1 | Nek7 inhibitors | Pending | 14-Sep-2022 | ||
| WO-2022241265-A1 | Inhibitors of the menin-mll interaction | Inactive | 14-May-2021 | ||
| US-11718601-B2 | Pyridinyl substituted oxoisoindoline compounds | Active | 06-Apr-2021 | ||
| US-20220324840-A1 | Pyridinyl substituted oxoisoindoline compounds | Active | 06-Apr-2021 | ||
| US-11572350-B1 | Benzothia(di)azepine compounds and their use as bile acid modulators | Active | 04-Dec-2020 | C07D285/36 |
Syngene International Signals
Syngene International Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Syngene International Investments (6)
Syngene International’s most recent deal was a Secondary Transaction - Private with O2 Renewable Energy V for . The deal was made on 16-Jan-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| O2 Renewable Energy V | 16-Jan-2026 | Secondary Transaction - Private | Other Energy Services | ||
| Emergent BioSolutions (Drug Substance Manufacturing Facility in Baltimore, Maryland ) | 19-Mar-2025 | Corporate Asset Purchase | Buildings and Property | ||
| Stelis Biopharma (Biologics Manufacturing Unit 3) | 01-Dec-2023 | Corporate Asset Purchase | Other Pharmaceuticals and Biotechnology | ||
| O2 Renewable Energy II | 27-Aug-2022 | Secondary Transaction - Private | Energy Production | ||
| AMPYR Renewable Energy Resources Eleven | 12-Jul-2022 | Secondary Transaction - Private | Special Purpose Acquisition Company (SPAC) |
Syngene International ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
14.66 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 67
Rank
Percentile
Syngene International FAQs
-
When was Syngene International founded?
Syngene International was founded in 1993.
-
Where is Syngene International headquartered?
Syngene International is headquartered in Bangalore, India.
-
What is the size of Syngene International?
Syngene International has 7,210 total employees.
-
What industry is Syngene International in?
Syngene International’s primary industry is Biotechnology.
-
Is Syngene International a private or public company?
Syngene International is a Public company.
-
What is Syngene International’s stock symbol?
The ticker symbol for Syngene International is 539268.
-
What is the current stock price of Syngene International?
As of 19-Nov-2026 the stock price of Syngene International is $4.68.
-
What is the current market cap of Syngene International?
The current market capitalization of Syngene International is $1.88B.
-
What is Syngene International’s current revenue?
The trailing twelve month revenue for Syngene International is $380M.
-
Who are Syngene International’s competitors?
Pharmaron, Reliance Life Sciences, Eurofins Scientific, WuXi AppTec, and Lupin are some of the 51 competitors of Syngene International.
-
What is Syngene International’s annual earnings per share (EPS)?
Syngene International’s EPS for 12 months was $0.05.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process